NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
Clinical Trials
10 trialsNCT00005847 2023-06-22
Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00003400 2019-11-04
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer
University of Maryland, Baltimore
Phase 2 Completed
NCT00003259 2019-06-26
Vinorelbine in Treating Patients With Metastatic Prostate Cancer
Swiss Cancer Institute
Phase 2 Completed
NCT00003622 2017-07-13
Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy
George Washington University
Phase 2 Withdrawn
NCT01155258 2016-06-13
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
University of Southern California
Phase 1 Completed
NCT00151086 2015-01-22
Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 1/2 Completed
NCT00627354 2011-05-16
Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006114 2011-03-01
Combination Chemotherapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00278070 2008-02-29
Metronomic Oral Vinorelbine in Patients With Metastatic Tumors
Hellenic Cooperative Oncology Group
Phase 2 Completed